French COVID-19 cases, patient numbers ease as AstraZeneca inoculations start
Reuters
Published Feb 06, 2021 03:11PM ET
Updated Feb 06, 2021 03:25PM ET
PARIS (Reuters) - France on Saturday reported a fall in new COVID-19 infections and in the number of patients being treated in hospital, slightly easing pressure on the health system as the country rolled out shots with a third approved vaccine.
The country registered 20,586 new confirmed COVID-19 cases, down from 22,139 the previous day and marking the third straight daily fall.
Hospitals were treating 27,369 people for the disease, down 245 from the previous day in a fourth consecutive daily fall.
The number of COVID-19 patients in intensive care eased to 3,225, down 20 from the previous day, data showed.
The government has resisted calls from health experts to impose a new national lockdown but the level of new cases per day has remained relatively steady above 20,000.
The number of people in France who have received their first dose of a COVID-19 vaccine has reached 1.86 million, with 247,260 having also received their second dose, the health ministry said.
France has received a batch of a COVID-19 vaccine developed by AstraZeneca (NASDAQ:AZN), with 273,600 doses delivered, the ministry said in an statement.
The initial AstraZeneca shots are being reserved for health personnel under 65, with first injections taking place on Saturday.
A second batch of 304,800 doses will be delivered next week.
AstraZeneca is the third shot to be made available in France after Pfizer/BioNTech and Moderna (NASDAQ:MRNA).
France is relying on the AstraZeneca shot to accelerate a vaccination campaign criticised for a slow start. However, it may obtain fewer deliveries than initially hoped after production setbacks sparked a row between the company and the European Union.
The ministry reported 191 new deaths linked to COVID-19, taking France's cumulative death toll in hospitals and nursing homes to 78,794.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.